Literature DB >> 25512494

Targeting osteosarcoma.

Darien E Reed1, Kevan M Shokat2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25512494      PMCID： PMC4280583          DOI： 10.1073/pnas.1420596111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  17 in total

1.  Characterization of canine osteosarcoma by array comparative genomic hybridization and RT-qPCR: signatures of genomic imbalance in canine osteosarcoma parallel the human counterpart.

Authors:  Andrea Y Angstadt; Alison Motsinger-Reif; Rachael Thomas; William C Kisseberth; C Guillermo Couto; Dawn L Duval; Dahlia M Nielsen; Jaime F Modiano; Matthew Breen
Journal:  Genes Chromosomes Cancer       Date:  2011-08-11       Impact factor: 5.006

2.  High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes.

Authors:  Edwin Choy; Francis Hornicek; Laura MacConaill; David Harmon; Zeeshan Tariq; Levi Garraway; Zhenfeng Duan
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

3.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.

Authors:  Jennifer A Perry; Adam Kiezun; Peter Tonzi; Eliezer M Van Allen; Scott L Carter; Sylvan C Baca; Glenn S Cowley; Ami S Bhatt; Esther Rheinbay; Chandra Sekhar Pedamallu; Elena Helman; Amaro Taylor-Weiner; Aaron McKenna; David S DeLuca; Michael S Lawrence; Lauren Ambrogio; Carrie Sougnez; Andrey Sivachenko; Loren D Walensky; Nikhil Wagle; Jaume Mora; Carmen de Torres; Cinzia Lavarino; Simone Dos Santos Aguiar; Jose Andres Yunes; Silvia Regina Brandalise; Gabriela Elisa Mercado-Celis; Jorge Melendez-Zajgla; Rocío Cárdenas-Cardós; Liliana Velasco-Hidalgo; Charles W M Roberts; Levi A Garraway; Carlos Rodriguez-Galindo; Stacey B Gabriel; Eric S Lander; Todd R Golub; Stuart H Orkin; Gad Getz; Katherine A Janeway
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-15       Impact factor: 11.205

6.  mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis.

Authors:  Quan Zhou; Zhansheng Deng; Yong Zhu; Haitao Long; Shaoxian Zhang; Jiali Zhao
Journal:  Med Oncol       Date:  2009-11-20       Impact factor: 3.064

7.  Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma.

Authors:  J F McIntyre; B Smith-Sorensen; S H Friend; J Kassell; A L Borresen; Y X Yan; C Russo; J Sato; N Barbier; J Miser
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

Review 8.  4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications.

Authors:  Gemma Armengol; Federico Rojo; Josep Castellví; Carmela Iglesias; Miriam Cuatrecasas; Berta Pons; José Baselga; Santiago Ramón y Cajal
Journal:  Cancer Res       Date:  2007-08-15       Impact factor: 12.701

9.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease.

Authors:  Carl R Walkley; Rameez Qudsi; Vijay G Sankaran; Jennifer A Perry; Monica Gostissa; Sanford I Roth; Stephen J Rodda; Erin Snay; Patricia Dunning; Frederic H Fahey; Frederick W Alt; Andrew P McMahon; Stuart H Orkin
Journal:  Genes Dev       Date:  2008-06-15       Impact factor: 11.361

10.  Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.

Authors:  Morris E Feldman; Beth Apsel; Aino Uotila; Robbie Loewith; Zachary A Knight; Davide Ruggero; Kevan M Shokat
Journal:  PLoS Biol       Date:  2009-02-10       Impact factor: 8.029
View more
  6 in total

1.  The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.

Authors:  Ling Wang; Fu-Biao Kang; Nan Sun; Juan Wang; Wei Chen; Dong Li; Bao-En Shan
Journal:  Tumour Biol       Date:  2016-09-20

Review 2.  Anticancer Effects of Constituents of Herbs Targeting Osteosarcoma.

Authors:  Qing-Hong Su; Xiao-Qun Xu; Jun-Fu Wang; Jun-Wen Luan; Xia Ren; Hai-Yan Huang; Si-Shan Bian
Journal:  Chin J Integr Med       Date:  2019-06-04       Impact factor: 1.978

3.  Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.

Authors:  Huensuk Kim; Seungyeul Yoo; Ruoji Zhou; An Xu; Jeffrey M Bernitz; Ye Yuan; Andreia M Gomes; Michael G Daniel; Jie Su; Elizabeth G Demicco; Jun Zhu; Kateri A Moore; Dung-Fang Lee; Ihor R Lemischka; Christoph Schaniel
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-01       Impact factor: 11.205

Review 4.  Monofunctional Platinum(II) Anticancer Agents.

Authors:  Suxing Jin; Yan Guo; Zijian Guo; Xiaoyong Wang
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-07

Review 5.  Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma.

Authors:  Zuozhang Yang; Xiaojuan Li; Yihao Yang; Zewei He; Xin Qu; Ya Zhang
Journal:  Cell Death Dis       Date:  2016-09-29       Impact factor: 8.469

6.  Whole-exome analysis in osteosarcoma to identify a personalized therapy.

Authors:  Chiara M Mazzanti; Claudio Di Cristofano; Caterina Chiappetta; Massimiliano Mancini; Francesca Lessi; Paolo Aretini; Veronica De Gregorio; Chiara Puggioni; Raffaella Carletti; Vincenzo Petrozza; Prospero Civita; Sara Franceschi; Antonio G Naccarato; Carlo Della Rocca
Journal:  Oncotarget       Date:  2017-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.